NEW DELHI: Alembic Pharmaceuticals group firm Rhizen Pharmaceuticals SA has entered into an exclusive worldwide license agreement with NovartisBSE 1.73 % for the development and commercialisation of a lead compound that could be used in the treatment of human airway disorders. Rhizen has inked a licensing pact with Novartis for the development and commercialisation of inhaled dual P13K-delta gamma inhibitor and its closely related compounds for various indications, Alembic Pharma said .. Read more at: http://economictimes.indiatimes.com/articleshow/50121708.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Source: Economic TimesAlembic Pharma arm ties up with Novartis for drug development
Industry: Pharmaceutical 2015-12-11
